Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Autor: Tsao AS; The University of Texas MD Anderson Cancer Center, Houston, TX., Miao J; SWOG Statistical Center, Seattle, WA., Wistuba II; The University of Texas MD Anderson Cancer Center, Houston, TX., Vogelzang NJ; US Oncology Comprehensive Cancer Centers of Nevada, Las Vegas, NV., Heymach JV; The University of Texas MD Anderson Cancer Center, Houston, TX., Fossella FV; The University of Texas MD Anderson Cancer Center, Houston, TX., Lu C; The University of Texas MD Anderson Cancer Center, Houston, TX., Velasco MR; Cancer Care Specialists of Illinois, Decatur, IL., Box-Noriega B; Kaiser Permanente, Fresno, CA., Hueftle JG; Montana Cancer Consortium, Billings, MT., Gadgeel S; University of Michigan, Ann Arbor, MI., Redman MW; SWOG Statistical Center, Seattle, WA., Gandara DR; University of California Davis Cancer Center, Sacramento, CA., Kelly K; University of California Davis Cancer Center, Sacramento, CA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2019 Oct 01; Vol. 37 (28), pp. 2537-2547. Date of Electronic Publication: 2019 Aug 06.